Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement

Tumori

Volumn 101, Issue 2, 2015, Pages e35-e39

  Rafee, Shereen ^a   Elamin, Yasir Y ^a   Joyce, Eimear ^a   Toner, Mary ^a   Flavin, Richard ^a   McDermott, Ronan ^a   Sheehy, Niall ^a   Hennessy, Bryan ^b   O'Byrne, Kenneth ^c   Gleeson, Noreen ^a   Osman, Nemer ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Anaplastic lymphoma kinase (ALK) gene; Crizotinib; Inflammatory myofibroblastic tumour (IMT)

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DOXORUBICIN; IFOSFAMIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ADULT; ALK GENE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DISEASE CLEARANCE; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PLASMA CELL GRANULOMA; POSITRON EMISSION TOMOGRAPHY; SALPINGOOOPHORECTOMY; TUMOR VOLUME; ABDOMINAL NEOPLASMS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DIFFERENTIAL DIAGNOSIS; GENE TRANSLOCATION; GENETICS; INFLAMMATION; NEOPLASMS, MUSCLE TISSUE; PATHOLOGY; PATIENT SATISFACTION; PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME;

ABDOMINAL NEOPLASMS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE REARRANGEMENT; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, MUSCLE TISSUE; PATIENT SATISFACTION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; QUALITY OF LIFE; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84930578858     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000245     Document Type: Article

References (33)

1. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19(8):859-872.
2. Pungpapong S, Geiger XJ, Raimondo M. Inflammatory myofibroblastic tumor presenting as a pancreatic mass: A case report and review of the literature. JOP. 2004;5(5):360-367.
3. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13(7):1537-1545.
4. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269-1275.
5. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61(4):428-437.
6. Brunn H. Two interesting benign lung tumors of contradictory histopathology. J Thorac Surg. 1939;9:119-131.
7. Coffin CM, Humphrey PA, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor: A clinical and pathological survey. Semin Diagn Pathol. 1998;15(2):85-101.
8. Wenig BM, Devaney K, Bisceglia M. Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm. Cancer. 1995;76(11):2217-2229.
9. Sciot R, Dal Cin P, Fletcher CD, et al. Inflammatory myofibroblastic tumor of bone: report of two cases with evidence of clonal chromosomal changes. Am J Surg Pathol. 1997;21(10): 1166-1172.
10. Ramachandra S, Hollowood K, Bisceglia M, Fletcher CDM. Inflammatory pseudotumour of soft tissues: A clinicopathological and immunohistochemical analysis of 18 cases. Histopathology. 1995;27(4):313-323.
11. Häusler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003;34(3):253-262.
12. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA. Inflammatory myofibroblastic tumor of the uterus: A clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol. 2005;29(10):1348-1355.
13. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31(4):509-520.
14. Firat O, Ozturk S, Akalin T, Coker A. Inflammatory myofibroblastic tumour. Can J Surg. 2009;52(3):E60-E61.
15. Meis JM, Enzinger FM. Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol. 1991;15(12): 1146-1156.
16. Germanidis G, Xanthakis I, Tsitouridis I, et al. Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment. Dig Dis Sci. 2005;50(2):262-265.
17. Li J, Yin WH, Takeuchi K, Guan H, Huang YH, Chan JK. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: A report of two cases and literature review. Diagn Pathol. 2013;8(1):147.
18. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK 1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14(6):569-576.
19. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127(5):707-722.
20. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK , the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002;34(4):354-362.
21. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159(2):411-415.
22. Mariño-Enríquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK . Am J Surg Pathol. 2011;35(1): 135-144.
23. Plesec TP. Gastrointestinal mesenchymal neoplasms other than gastrointestinal stromal tumors: focusing on their molecular aspects. Pathol Res Int. 2011;2011:952569.
24. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
25. Gomes Karen, Ella Sugo, Draga Barbaric and Toby Trahair. "Rapid regression of life threatening ALK positive epithelioid inflammatory myofibroblastic sarcoma following single agent crizotinib therapy". In Asia-Pacific Journal Of Clinical Onclogy, vol. 8, pp. 300-300. 111 River St, Hoboken 07030-5774, NJ USA: Wiley-Blackwell, 2012.
26. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALKrearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727-1733.
27. Su W, Ko A, O'Connell T, Applebaum H. Treatment of pseudotumors with nonsteroidal antiinflammatory drugs. J Pediatr Surg. 2000;35(11):1635-1637.
28. Chan PW, Omar KZ, Ramanujam TM. Successful treatment of unresectable inflammatory pseudotumor of the lung with COX-2 inhibitor. Pediatr Pulmonol. 2003;36(2):167-169.
29. Chavez C, Hoffman MA. Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature. Oncol Lett. 2013;5(5):1672-1676.
30. Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4(8):889-895.
31. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol. 2012;30(Suppl):abstr 7508.
32. Heigener DF, Reck M. Crizotinib. In: Martens UM, ed. Small Molecules in Oncology. Berlin, Heidelberg: Springer;2014:197-205.
33. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010;70(24):10038-10043.